Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 373.1 Billion KRW | -0.76% |
| 2022 | 375.96 Billion KRW | 6.11% |
| 2021 | 354.32 Billion KRW | 15.15% |
| 2020 | 307.7 Billion KRW | 36.96% |
| 2019 | 224.67 Billion KRW | 15.86% |
| 2018 | 193.91 Billion KRW | 26.86% |
| 2017 | 152.86 Billion KRW | -24.53% |
| 2016 | 202.55 Billion KRW | 50.05% |
| 2015 | 134.98 Billion KRW | 28.5% |
| 2014 | 105.05 Billion KRW | -2.35% |
| 2013 | 107.57 Billion KRW | -15.43% |
| 2012 | 127.21 Billion KRW | 2.25% |
| 2011 | 124.41 Billion KRW | 54.28% |
| 2010 | 80.64 Billion KRW | 52.82% |
| 2009 | 52.77 Billion KRW | 13.67% |
| 2008 | 46.42 Billion KRW | 1.17% |
| 2007 | 45.88 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 439.48 Billion KRW | 1.17% |
| 2024 Q1 | 434.38 Billion KRW | 16.42% |
| 2023 Q3 | 391.04 Billion KRW | 5.69% |
| 2023 Q2 | 370 Billion KRW | -14.1% |
| 2023 FY | 373.1 Billion KRW | -0.76% |
| 2023 Q1 | 430.74 Billion KRW | 14.57% |
| 2023 Q4 | 373.1 Billion KRW | -4.59% |
| 2022 Q2 | 371.87 Billion KRW | -1.67% |
| 2022 FY | 375.96 Billion KRW | 6.11% |
| 2022 Q4 | 375.96 Billion KRW | -4.42% |
| 2022 Q3 | 393.37 Billion KRW | 5.78% |
| 2022 Q1 | 378.18 Billion KRW | 6.73% |
| 2021 Q2 | 328.65 Billion KRW | 4.14% |
| 2021 Q3 | 336.26 Billion KRW | 2.31% |
| 2021 Q4 | 354.32 Billion KRW | 5.37% |
| 2021 FY | 354.32 Billion KRW | 15.15% |
| 2021 Q1 | 315.58 Billion KRW | 2.56% |
| 2020 Q3 | 341.54 Billion KRW | 16.06% |
| 2020 FY | 307.7 Billion KRW | 36.96% |
| 2020 Q4 | 307.7 Billion KRW | -9.91% |
| 2020 Q1 | 207.3 Billion KRW | -7.73% |
| 2020 Q2 | 294.29 Billion KRW | 41.96% |
| 2019 FY | 224.67 Billion KRW | 15.86% |
| 2019 Q4 | 224.67 Billion KRW | -1.2% |
| 2019 Q3 | 227.4 Billion KRW | 4.34% |
| 2019 Q2 | 217.93 Billion KRW | -0.57% |
| 2019 Q1 | 219.19 Billion KRW | 13.04% |
| 2018 Q4 | 193.91 Billion KRW | -3.64% |
| 2018 Q2 | 162.72 Billion KRW | 0.77% |
| 2018 FY | 193.91 Billion KRW | 26.86% |
| 2018 Q1 | 161.48 Billion KRW | 5.64% |
| 2018 Q3 | 201.24 Billion KRW | 23.67% |
| 2017 Q1 | 225.56 Billion KRW | 11.36% |
| 2017 Q2 | 199.95 Billion KRW | -11.35% |
| 2017 Q4 | 152.86 Billion KRW | -32.49% |
| 2017 Q3 | 226.43 Billion KRW | 13.24% |
| 2017 FY | 152.86 Billion KRW | -24.53% |
| 2016 Q4 | 202.55 Billion KRW | 0.0% |
| 2016 FY | 202.55 Billion KRW | 50.05% |
| 2015 Q2 | 115.16 Billion KRW | 4.57% |
| 2015 FY | 134.98 Billion KRW | 28.5% |
| 2015 Q4 | 134.98 Billion KRW | -1.13% |
| 2015 Q3 | 136.53 Billion KRW | 18.55% |
| 2015 Q1 | 110.13 Billion KRW | 4.84% |
| 2014 Q3 | 118.25 Billion KRW | 13.55% |
| 2014 Q4 | 105.05 Billion KRW | -11.17% |
| 2014 FY | 105.05 Billion KRW | -2.35% |
| 2014 Q1 | 106.95 Billion KRW | -0.58% |
| 2014 Q2 | 104.14 Billion KRW | -2.63% |
| 2013 Q3 | 126.37 Billion KRW | 12.18% |
| 2013 Q4 | 107.57 Billion KRW | -14.88% |
| 2013 FY | 107.57 Billion KRW | -15.43% |
| 2013 Q1 | 121.69 Billion KRW | -4.34% |
| 2013 Q2 | 112.65 Billion KRW | -7.43% |
| 2012 Q2 | 127.24 Billion KRW | -3.54% |
| 2012 Q1 | 131.91 Billion KRW | 6.03% |
| 2012 FY | 127.21 Billion KRW | 2.25% |
| 2012 Q4 | 127.21 Billion KRW | -8.74% |
| 2012 Q3 | 139.39 Billion KRW | 9.55% |
| 2011 Q3 | 128.58 Billion KRW | 14.3% |
| 2011 FY | 124.41 Billion KRW | 54.28% |
| 2011 Q1 | 111.03 Billion KRW | 37.68% |
| 2011 Q4 | 124.41 Billion KRW | -3.24% |
| 2011 Q2 | 112.49 Billion KRW | 1.32% |
| 2010 Q1 | 75.66 Billion KRW | 43.37% |
| 2010 FY | 80.64 Billion KRW | 52.82% |
| 2010 Q4 | 80.64 Billion KRW | -7.82% |
| 2010 Q3 | 87.48 Billion KRW | 7.91% |
| 2010 Q2 | 81.07 Billion KRW | 7.16% |
| 2009 Q1 | 50.46 Billion KRW | 8.7% |
| 2009 FY | 52.77 Billion KRW | 13.67% |
| 2009 Q4 | 52.77 Billion KRW | -9.78% |
| 2009 Q3 | 58.49 Billion KRW | 19.69% |
| 2009 Q2 | 48.87 Billion KRW | -3.16% |
| 2008 Q2 | 42.24 Billion KRW | -19.95% |
| 2008 Q4 | 46.42 Billion KRW | -2.26% |
| 2008 Q3 | 47.5 Billion KRW | 12.45% |
| 2008 FY | 46.42 Billion KRW | 1.17% |
| 2008 Q1 | 52.76 Billion KRW | 14.98% |
| 2007 FY | 45.88 Billion KRW | 0.0% |
| 2007 Q1 | 58.59 Billion KRW | 0.0% |
| 2007 Q3 | 48.54 Billion KRW | 4.64% |
| 2007 Q4 | 45.88 Billion KRW | -5.47% |
| 2007 Q2 | 46.39 Billion KRW | -20.83% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -379.218% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 59.872% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 47.234% |
| HANDOK Inc. | 449.7 Billion KRW | 17.033% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -335.517% |
| Yuhan Corporation | 712.33 Billion KRW | 47.622% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 40.956% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -2247.41% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 56.199% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -597.027% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -81.23% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -396.347% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -152.451% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -429.974% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -379.218% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -924.004% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -48.56% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -69.053% |
| JW Holdings Corporation | 827.51 Billion KRW | 54.912% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | 14.619% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 36.416% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 1.71% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -370.494% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -433.259% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -53.636% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -12.963% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -379.218% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | 23.858% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 56.516% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 1.71% |
| Yuhan Corporation | 712.33 Billion KRW | 47.622% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | 21.913% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -172.405% |
| Suheung Co., Ltd. | 516.66 Billion KRW | 27.786% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | 1.71% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -141.438% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -314.725% |
| CKD Bio Corp. | 170.76 Billion KRW | -118.498% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -53.08% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -136.659% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -767.309% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -370.494% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 41.012% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -79.209% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -81.23% |
| JW Lifescience Corporation | 96.44 Billion KRW | -286.869% |